VP45.23: Fetal sonographic follow‐up after maternal COVID‐19 infection: is there a matter of concern?

Objectives

Although there is no evidence of vertical transmission of COVID‐19, fetal consequences of maternal COVID‐19 remain unknown. The objective of the present study is to assess the impact of COVID‐19 during pregnancy in terms of adverse perinatal outcomes, intrauterine growth restriction, fetal cardiac or neurosonographic abnormalities, and identify the association with maternal severity of COVID‐19 disease or with gestational age at infection.

Methods

Multicentric prospective cohort study including singleton pregnant women with diagnosis of SARS‐CoV2 infection in 5 hospitals in Spain, starting from April 2020. Inclusion will continue until the end of the pandemic, with a minimum estimated sample size of 100 women. Maternal infection will be confirmed by nasopharyngeal PCR in the acute phase, or by further serologic test, and COVID‐19 clinical presentation parameters will be collected. Once the patient has overcome the disease, ultrasound follow‐up will be performed, including fetal growth assessment every 4 weeks, fetal neurosonography and echocardiographic evaluation in the third trimester, at least 4 weeks after maternal infection. All patients will be followed‐up until delivery and perinatal outcome will be assessed. Analysis of associated factors related with echographic findings will be performed.

Results

We hypothesised that patients with severe COVID‐19 disease have a higher risk of adverse perinatal outcome, fetal growth restriction, neurodevelopmental impairment and/or fetal cardiac function remodelling. To date a total of 52 patients have been included and results will be available by the end of September.

Conclusions

This study will provide relevant information of fetal consequences of COVID‐19 during pregnancy depending on maternal severity or trimester of infection.